Full text
Earnings transcript
Read the complete earnings call transcript.
IQV
IQVIA Holdings Inc.
$166.16
2.31
(1.41%)
| Exchange: | NYSE |
| Market Cap: | 28.197B |
| Shares Outstanding: | 125.468M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Ari Bousbib | |||||
| Full Time Employees: | 89000 | |||||
| Address: |
|
|||||
| Website: | https://www.iqvia.com |
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 14,984,000 | 15,405,000 | 16,310,000 |
| Gross Profit | 5,239,000 | 5,375,000 | 4,286,000 |
| EBITDA | 3,256,000 | 3,453,000 | 3,464,000 |
| Operating Income | 1,977,000 | 2,202,000 | 2,287,000 |
| Net Income | 1,358,000 | 1,373,000 | 1,360,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 26,681,000 | 26,899,000 | 29,944,000 |
| Total Liabilities | 20,569,000 | 20,832,000 | 23,314,000 |
| Total Stockholders Equity | 6,112,000 | 6,067,000 | 6,503,000 |
| Total Debt | 13,896,000 | 14,156,000 | 16,174,000 |
| Cash and Cash Equivalents | 1,376,000 | 1,702,000 | 1,980,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 2,149,000 | 2,716,000 | 2,654,000 |
| Capital Expenditure | -649,000 | 0 | 0 |
| Free Cash Flow | 1,500,000 | 2,716,000 | 2,654,000 |
| Net Income | 1,358,000 | 1,373,000 | 1,361,000 |
| Net Change in Cash | 160,000 | 326,000 | 278,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 21,538,075.780 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 22,100,256.042 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 21,761,500 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 4,545,149.942 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 4,663,786.054 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 4,592,298.842 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 3,338,663.989 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 3,452,304.754 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 3,383,827.774 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 2,904,037.839 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,979,838.146 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 2,934,162.740 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 19.500 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 19.900 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 19.240 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 13 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 6 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates IQV intrinsic value between $217.91 – $231.26 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about IQV valuation
Is IQV (IQV) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for IQV (IQV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is IQV a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether IQV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is IQV’s P/E ratio?
You can see IQV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for IQV?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is IQV a good long-term investment?
Whether IQV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
IQV
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
1.41
Trading Metrics:
| Open: | Previous Close: | |||
| Day Low: | Day High: | |||
| Year Low: | Year High: | |||
| Price Avg 50: | Price Avg 200: | |||
| Volume: | Average Volume: |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
Relevant news
